Gibson Dunn & Crutcher advised Spyre Therapeutics, Inc. on the offering, and Covington & Burling advised the underwriters. Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here